HCM(和黄医药 (HUTCHMED)) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $356.13M | $426.41M | $838.00M | $630.20M | $548.51M |
| 毛利润 | — | $115.31M | $453.55M | $281.32M | $212.16M |
| 营业利润 | −$328.32M | −$407.69M | $18.38M | −$43.70M | −$39.16M |
| 净利润 | −$194.65M | −$360.83M | $100.78M | $37.73M | $456.91M |
| 经营现金流 | −$204.22M | −$268.60M | $219.26M | $497.00K | −$64.66M |
| 自由现金流 | −$220.62M | −$305.26M | $186.65M | −$17.44M | −$78.81M |
| 摊薄每股收益 | $-0.25 | $-0.43 | $0.12 | $0.04 | $0.52 |